Justin Kim
Stock Analyst at Oppenheimer
(0.85)
# 3,714
Out of 4,761 analysts
36
Total ratings
32.14%
Success rate
-12.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $27.52 | +45.35% | 6 | Nov 6, 2024 | |
| PHVS Pharvaris | Maintains: Outperform | $38 → $42 | $16.49 | +154.70% | 4 | Sep 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $50.26 | +110.90% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $29.92 | +190.78% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $28.58 | -9.03% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $6.69 | - | 2 | Oct 17, 2023 | |
| ZURA Zura Bio | Initiates: Outperform | $17 | $1.40 | +1,114.29% | 1 | Aug 25, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $7.93 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $9.21 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $32.32 | +82.55% | 1 | Jul 18, 2022 |
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $27.52
Upside: +45.35%
Pharvaris
Sep 6, 2024
Maintains: Outperform
Price Target: $38 → $42
Current: $16.49
Upside: +154.70%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $50.26
Upside: +110.90%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $29.92
Upside: +190.78%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $28.58
Upside: -9.03%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $6.69
Upside: -
Zura Bio
Aug 25, 2023
Initiates: Outperform
Price Target: $17
Current: $1.40
Upside: +1,114.29%
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.93
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $9.21
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $32.32
Upside: +82.55%